Navigation Links
Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
Date:7/15/2011

ctors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Neither Janssen Pharmaceuticals, Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.) Media Contacts Marc Boston

215-273-7649 (office)

215-429-7034 (mobile) Bill Price

732-524-6623 (office)
732-668-3735 (mobile)Investor Relations ContactsJohnson & JohnsonLesley Fishman

732-524-3922 (office)Ellen Sipos
732 524-3709 (office)
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dr. Napoleone Ferrara Wins 2011 Dr. Paul Janssen Award for Biomedical Research
2. Janssen Products, LP Modifies Prescribing Information for PROCRIT® (Epoetin alfa) in Chronic Kidney Disease
3. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
4. Record Breaking $327 Million Verdict Announced in Janssen Case
5. MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness
6. Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
7. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
8. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
9. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
10. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
11. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 30, 2015 Roche (SIX: RO, ROG; OTCQX: ... EGFR Mutation Test v2 for Premarket Approval (PMA) ... as a companion diagnostic test for AZD9291, an ... patients with an acquired resistant mutation.  ... have adenocarcinoma with tumor containing an EGFR sensitizing ...
(Date:7/29/2015)... Calif. , July 29, 2015  UBM Canon ... San Diego Marriott Marquis & Marina on September 1-2, ... device industry. A highlight of the Business Development track ... Backing from Different Types of Investors, featuring Renee ... Johnson Development Corporation; Brent Ahrens , Partner, Canaan ...
(Date:7/29/2015)... Calif. and CAMBRIDGE, Mass. ... Inc. (NASDAQ: ISIS ), the leader in ... subsidiary, announced today that The New England ... a Phase 2 clinical study evaluating volanesorsen (formerly ... to severely high triglycerides. This publication follows the ...
Breaking Medicine Technology:Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 2Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 3Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 4Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 5Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 6Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 7
... 24, 2011 Molecular Devices, Inc. and ChanTest Corporation, ... tools and solutions, have signed an agreement for Molecular ... and GPCR cell lines on a non-exclusive basis.  As ... ChanTest,s ion channel and GPCR cell lines and promote ...
... MELVILLE, N.Y., March 24, 2011 Henry Schein, Inc. ... health care products and services to office-based dental, medical ... the "Wholesalers:  Health Care" industry in Fortune ... the categories of Social Responsibility and Global Competitiveness.  The ...
Cached Medicine Technology:Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement 2Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement 3Henry Schein Ranks #1 in Its Industry for Social Responsibility as a Fortune 2011 World's Most Admired Company 2Henry Schein Ranks #1 in Its Industry for Social Responsibility as a Fortune 2011 World's Most Admired Company 3
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd Clay Today Online ... to fund the state’s large prison system, which has amassed largely enough throughout the ... incarceration. In light of President Obama’s recent reduction of non violent drug offender’s prison ...
(Date:7/30/2015)... ... , ... Gummy smile surgeon, Dr. Alex Farnoosh, now offers comprehensive ... as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist with decades ... around the world. , “Like treatment of any other disease or condition, making the ...
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... ... , ... Author Dr. Raul Llanos seeks to empower readers to ... book, “ Consciously Healing our Webs of Health, Wellbeing, Success, and Abundance ” (published ... responsibility for ourselves, we can create better realities.” His book illustrates the possibilities of ...
(Date:7/30/2015)... ... , ... After a three year trial designed to study the efficiency and ... “bionic eye,” researchers have determined the trial to be a success, and are recommending ... affected by complete vision loss as a result of Retinitis pigmentosa. The results of ...
Breaking Medicine News(10 mins):Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
... common cancer drug imatinib (Gleevec), researchers have eliminated morphine ... the effectiveness of chronic pain management in patients, according ... Cancer Center. Narcotics such as morphine are a ... the pain-relieving effects of these drugs can develop, requiring ...
... caused by an erosion of the protective caps on chromosomes, ... allows malignant cells to evade destruction and acquire more deadly ... journal Cell . In a strain of ... through this two-step process developed lethal cancer and 25 percent ...
... A Cedars-Sinai research scientist has been awarded two ... prestigious Research Project Grant from the National Institutes of ... Terrence Town, PhD, is studying drugs that ... amyloid plaques that build up in the brain and ...
... HealthDay Reporter , MONDAY, Feb. 20 (HealthDay News) -- Alcohol ... new national survey reveals. The online, anonymous poll indicated ... abuse or dependence: nearly 14 percent of male surgeons and ... 8 percent to 12 percent figure typically cited for alcohol ...
... Institute researchers will lead a symposium on relationships between ... autism in children during the American Association for the ... in Vancouver, Canada. The symposium, "Autism: Genetic, Epigenetic ... Feb. 18. The researchers, both affiliated with the UC ...
... Alzheimer,s disease drugs now being tested in clinical trials ... Northwestern Medicine research. A study with mice suggests the ... to be miswired and interfering with their ability to ... the scientist whose original research led to the drug ...
Cached Medicine News:Health News:Reformulated imatinib eliminates morphine tolerance in lab studies 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 3Health News:Cedars-Sinai awarded $2.5 million to study potential new drug treatments for Alzheimer's disease 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 3Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 4Health News:UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver 2Health News:Alzheimer's drugs may have adverse side effects 2
... The full color LCD ... familiar joystick controls, enable any ... make quick and accurate measurements.,Measurement ... the color screen, and results ...
... Patients who need punctal ... dry eye relief. They also ... be as comfortable and as ... why Alcon punctal plugs are ...
... to diagnostic images and reports, the powerful ... scaled to meet the needs of virtually ... Web PACS system allows clinicians, referring physicians, ... view images and information on-site or at ...
... SonoAce 9900 is a ... ultrasound system, with an ... DICOM compatible, designed for ... imaging, obstetrics, gynecology, perinatology, ...
Medicine Products: